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Familial hypertrophic cardiomyopathy (FHC) is a disease of cardiac sarcomeres. To identify molecular mechanisms underlying
FHC pathology, functional and structural diﬀerences in three FHC-related mutations in recombinant α-Tm (V95A, D175N, and
E180G) were characterized using both conventional and modiﬁed in vitro motility assays and circular dichroism spectroscopy.
Mutant Tm’s exhibited reduced α-helical structure and increased unordered structure. When thin ﬁlaments were fully occupied
by regulatory proteins, little or no motion was detected at pCa 9, and maximum speed (pCa 5) was similar for all tropomyosins.
Ca2+-responsiveness of ﬁlament sliding speed was increased either by increased pCa50 (V95A), reduced cooperativity n (D175N),
or both (E180G). When temperature was increased, thin ﬁlaments with E180G exhibited dysregulation at temperatures ∼10◦C
lower, and much closer to body temperature, than WT. When HMM density was reduced, thin ﬁlaments with D175N required
fewer motors to initiate sliding or achieve maximum sliding speed.
1.Introduction
Familial hypertrophic cardiomyopathy (FHC) is a disease
of cardiac sarcomeres, with causal mutations identiﬁed in
a variety of myoﬁlament proteins including thin ﬁlament
Ca2+-regulatory proteins [1–5]. Many mutations in car-
diac troponin I (cTnI, the inhibitory subunit of the tro-
ponin complex, Tn) and cardiac troponin T (cTnT, Tn’s tro-
pomyosin-binding subunit) enhance contractile function at
subsaturating,andinsomeinstancesatsaturating[Ca2+][6–
13]. Cardiac α-tropomyosin (α-Tm) is a third component
of the thin ﬁlament associated with FHC [14, 15] that
could have a central role in functional enhancement by FHC
mutations, at least at subsaturating levels of [Ca2+], although
wild-type Tm by itself (i.e., in the absence of Tn) does not
enhance function [7, 16, 17].2 Journal of Biomedicine and Biotechnology
T h eT mm o l e c u l ei sa nα-helical coiled-coil dimer that
binds head to tail with adjacent Tm’s to form a continuous
strand, with two Tm strands associated with an F-actin
[18]. Each Tm is associated with seven actin monomers and
one ternary complex of Tn to form a structural regulatory
unit that blocks strong myosin cross-bridge formation in
the absence of Ca2+ (blocked state) [19]. Ca2+ binding to
troponin C (TnC, Tn’s Ca2+-binding subunit) permits Tm
movement on the thin ﬁlament to partially expose strong
cross-bridge binding sites on actin (closed state), with
further movement to the open state upon binding of myosin
[19]. Some FHC mutations in α-Tm have been shown to
reduce Tm’s aﬃnity for actin in vitro in the absence of Tn
[20, 21] and may additionally destabilize Tn binding [22];
they further reduce the thermal stability of α-helix structure
content in isolated Tm [21, 23, 24] or in actin-Tm [24].
It is not known, however, to what extent these structural
changes and changes in thermal stability of Tm inﬂuence the
function of regulated thin ﬁlaments.
Several FHC mutations in Tm may enhance some aspects
of actomyosin function, but only at subsaturating and not
saturating [Ca2+]. V95A increased Ca2+-sensitivity but also
caused small decreases in the maximum solution ATPase ac-
tivity, maximum speed of ﬁlament sliding in motility assays,
and maximum Ca2+-activatable tension in thin ﬁlament-re-
constituted cardiac preparations [15, 22, 25]. E180G in-
creased Ca2+-sensitivity of tension in thin ﬁlament-recon-
stituted cardiac preparations [25], and both D175N and
E180G increased Ca2+-sensitivity of the fraction of motile
ﬁlaments in motility assays [26]. Maximum ﬁlament sliding
speed was unchanged by D175N or E180G when the ternary
complex of cardiac Tn (cTn) was used [26] but increased
with skeletal Tn (sTn) [20]. Vastus lateralis ﬁbers from pa-
tients with the D175N mutation exhibited increased Ca2+-
sensitivity of isometric force compared with control ﬁbers,
with no change in maximum force or shortening velocity
[27]. Maximum Ca2+-activatable tension in thin ﬁlament-
reconstituted cardiac preparations was decreased for D175N
butnotE180G,whiletotalmaximumtensionwasunchanged
for D175N but increased for E180G; this was attributable
to increases in Ca2+-independent tension for both D175N
and E180G, and V95A, too [25]. In a transgenic (Tg) mouse
model,theE180Gmutationleadstocardiachypertrophyand
increased mortality [28, 29]. These results from disparate
assays indicate that FHC-related mutations require more
thorough functional analysis at the level of single thin ﬁla-
ments to understand molecular mechanisms of the disease,
and to allow for testing of potential therapeutic agents.
We therefore examined the inﬂuence of three FHC
mutants in α-Tm on structure and Ca2+ activation of cardiac
thin ﬁlaments under unloaded conditions. Thin ﬁlaments
were reconstituted from recombinant, human α-GS-Tm WT,
mutants E180G, D175N, or V95A, and cTn, and in vitro
motility assays were used to examine function at the level
of individual ﬁlaments. The three mutants increased Ca2+-
responsiveness of ﬁlament sliding speed at 30◦Cw i t hn o
change in the maximum or minimum speeds at pCa 5 or
pCa 9, respectively, when thin ﬁlaments were saturated with
regulatory proteins. Increased Ca2+-responsiveness by FHC
mutations was associated with greater structural disorder
by circular dichroism spectroscopy (CD) at 25◦C; E180G
exhibited reduced functional stability at ∼10◦C lower than
WT when temperature was varied in motility assays at pCa 5.
Cross-bridge duty ratio was lower by ∼30% with regulated
thin ﬁlaments at pCa 5 and 30◦C than with unregulated
F-actin; duty ratio was similarly lower for thin ﬁlaments
reconstituted with cTn and mutants D175N and E180G. In
addition, enhancement of sliding speed for thin ﬁlaments
reconstituted with D175N occurred at lower HMM densities
than for WT or E180G. These results support the hypothesis
that structural destabilization of α-Tm may play a role in
functional enhancement by FHC-related mutations when
there are few cross-bridges and could in some cases lead
to loss of regulation (diastolic dysfunction) under normally
minor perturbations of cellular conditions such as slight
elevation of body core temperature during exercise.
2.MaterialsandMethods
2.1. Tropomyosin. Full-length human α-Tm (accession no.
M19713) and, for comparison in structural assays, β-Tm
(accession no. X06825) cDNAs were PCR ampliﬁed from a
Marathon-Ready cDNA Library (CLONTECH Laboratories
Inc., Palo Alto, Calif, USA) made from human cardiac tissue.
Both PCR products were conﬁrmed by sequencing. The α-
and β-Tm constructs were engineered with a BamHI site just
before the start codon and a SalI site just after the stop codon
by PCR using Pfu Turbo DNA polymerase (Stratagene Inc.,
Cedar Creek, Tex, USA). Inserts were ligated to maltose-
binding protein (MBP) fusion expression vector pMAL-c2
(New England BioLabs Inc., Beverly, Mass, USA) in which a
thrombin cleavage site had been engineered. DH5α cells were
transformed with the ligation mixtures, and the positive
clones were identiﬁed by PCR with the same primers used
for cloning. The recombinant plasmids were extracted for
expression and mutagenesis (α-Tm only).
Three α-Tm mutants, α-TmV95A, D175N, and E180G,
were generated by PCR using QuikChange XL Site-Directed
Mutagenesis system (Stratagene). Reactions were carried out
per manufacturer’s instructions with the template of α-
Tm/pMAL-c2 plasmid and primer pairs:
pTmV95Af: 5 -CGCATCCAGCTGGCTGAGGAA-
GAGTTGG-3 
pTmV95Ar: 5 -CCAACTCTTCCTCAGCCAGCTG-
GATGCG-3 
pTmD175Nf: 5 -GGTCATCATTGAGAG-
CAACCTGGAACGTGC-3 
pTmD175Nr: 5 -GCACGTTCCAGGTTGCTCTC-
AATGATGACC-3 
pTmE180Gf: 5 -CGACCTGGAACGTGC-
AGGAGAGCGGGCTGAGCTCTC-3 
pTmE180Gr: 5 -GAGAGCTCAGCCCGC-
TCTCCTGCACGTTCCAGGTCG-3 
Plasmids extracted from three transformed mutants were
sequenced with primers targeted at the ﬂanks of MCS onJournal of Biomedicine and Biotechnology 3
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Figure 1: SDS-PAGE analysis of representative protein prepara-
tions. Gel was 4–12% polyacrylamide gradient (Invitrogen) and
was stained with Coomassie brilliant blue. Lanes 1 and 11: MW
markers (Invitrogen See Blue Plus 2; MWs given at right). Lane
2: rabbit skeletal muscle HMM. Lane 3: rabbit skeletal muscle
actin.Lane4:recombinantratcardiactroponin(forreferenceonly).
Lane 5: human cTn (HcTn; Research Diagnostics). Lane 6: recom-
binant β-GS-Tm WT. Lane 7: recombinant α-GS-Tm WT. Lane
8: recombinant α-GS-Tm E180G. Lane 9: recombinant α-GS-Tm
D175N. Lane 10: recombinant α-GS-Tm V95A.
pMAL-c2 vector to conﬁrm sequence changes in the mu-
tants.
For expression, competent E. coli BL21 (DE3)c e l l s
(Novagen Inc., Madison, Wis, USA) were transformed with
cDNA/pMAL-c2 plasmids for α-Tm, β-Tm, or the α-Tm
mutants. Single colonies were grown at 37◦Ct oa nO D 600 of
0.5, followed by IPTG induction. The cells were harvested,
resuspended in column buﬀer (20mM Tris.Cl, pH 7.4,
10mMβ-mercaptoethanol,200mMNaCl,and1mMEDTA),
lysed with mild sonication, centrifuged at 12,000g, passed
over an amylose aﬃnity column (New England BioLabs
Inc.), and eluted with column buﬀer containing 10mM mal-
tose. Fusion proteins were cleaved with thrombin (Sigma, St.
Louis, Mo, USA) at 1 unit of thrombin per mg of protein in
column buﬀer for 4hrs at room temperature. The liberated
recombinant Tm homodimers were puriﬁed on a Mono Q
column (Pharmacia Biotech, Uppsala, Sweden) by high per-
formance liquid chromatography (HPLC) with a gradient
elution (buﬀer A: 20mM Tris·Cl, pH 8.0, 25mM NaCl; buﬀ-
er B: buﬀer A containing 500mM NaCl). The BamHI site
on pMAL-c2 vector is integral to the thrombin cleavage re-
gion so all recombinant Tm’s have two extra-amino acids
(GS-) at the N-terminus; GS-represents a conservative alter-
native to the AS-dipeptide in bacterially expressed Tm that
substitutes functionally for N-terminal acetylation [21, 30].
The puriﬁed recombinant proteins (Figure 1)w e r ec o n c e n -
trated, aliquoted, and stored at −80◦Ci nH P L Ce l u t i o nb u f -
fer until use [22, 25, 31].
2.2. Myosin, Heavy Meromyosin, Actin, and Troponin. Myo-
sin and muscle acetone powder were made from rabbit back
and leg muscles as previously described [8, 31–34]. Animal
handling was in accordance with the current US National
Institutes of Health/National Research Council Guide for
the Care and Use of Laboratory Animals.A l lp r o c e d u r e sa n d
protocols were approved by Florida State University’s Insti-
tutional Animal Care and Use Committee. Adult male New
Zealand white rabbits were anesthetized with 10mg/kg
Xylazine + 50mg/kg of Ketamine + 3mg Acepromazine in
physiological saline (IM). Following veriﬁcation of appro-
priate surgical depth of anesthesia, the animal was exsan-
guinated, skinned, eviscerated, and chilled on ice. Back and
leg muscles were removed for the isolation of the desired
proteins. F-actin was prepared from muscle acetone powder;
aliquots of F-actin were labeled with rhodamine-phalloidin
(RhPh) for ﬂuorescence microscopy [8, 31, 32, 35]. Heavy
meromyosin (HMM) was prepared by chymotryptic diges-
tion of myosin [8, 31, 32, 35]. Native human cardiac tro-
ponin (HcTn) was obtained from Research Diagnostics
(Flanders, NJ, USA). SDS-PAGE analysis of representative
batches of proteins is shown in Figure 1.
2.3. SDS-PAGE and Western Blotting. Proteins were analyzed
by SDS-PAGE and Western blotting. SDS-PAGE was con-
ducted with 4–12% SDS-PAGE gels (Invitrogen Inc., Carls-
bad, Calif, USA). Gels were either stained with Coomassie
brilliant blue (Sigma) to visualize proteins (Figure 1)a n d
analyzed with an EDAS-290 digital imaging system (Kodak,
Rochester, NY, USA), or were used to transfer proteins to
nitrocellulose (NC) membranes (BIO-RAD, Hercules, Calif,
USA) at 30mA, 4◦C for overnight. NC membranes were
r i n s e df o r2m i ni nT B S - Tb u ﬀer (20mM Tris·Cl, 150mM
NaCl, 0.05% Tween-20, pH 7.5), blocked for 1hr at room
temperature in TBS-T containing 2% BSA (Sigma), then
incubated with rabbit anti-Tm antibody (Sigma, T3651) in
TBS-T (1:3000) for 1 hr at room temperature. Bound anti-
body was detected using horseradish peroxidase-conjugated
anti-rabbit IgG, followed by enhanced chemiluminescence
reaction with ECL Plus Kit (Amersham Biosciences, Little
Chalfont, Buckinghamshire, UK). Finally, the blots were
exposed to Kodak X-ray ﬁlm (Kodak, Rochester, NY, USA).
2.4. Circular Dichroism Spectroscopy. α-Tm, β-Tm, and three
α-Tm mutants were dialyzed against CD buﬀer (20mM
sodium phosphate, 20mM NaCl, pH 7.4) and concentrated
using Centricon concentrators of 30,000MW cut oﬀ (Mil-
lipore Corporation, Bedford, Mass, USA). Protein concen-
tration was determined in CD buﬀer (in absence or presence
[36]o f6Mu r e a )f r o mA 280 using an extinction coeﬃcient of
8700M−1 cm−1 (http://us.expasy.org/). Data were collected
at Tm concentrations of ∼3–9μMo na nA V I Vm o d e l2 0 2
spectrometer (Aviv Biomedical Inc, Lakewood, NJ, USA) us-
ing a 1mm cuvette and wavelength range of 190–260nm at
25◦C. Each sample was equilibrated for 10min prior to data
collection and scanned three times with 0.4 or 0.5nm wave-
length steps and averaging time of 1s. Molar ellipticity at
222nm ([θ]222) was used to calculate α-helix content [37],
and the elements of the secondary structure were analyzed
with CDPro [38] using basis set 4. CD data represent the
average of 2-3 independent experiments. The instrument4 Journal of Biomedicine and Biotechnology
was calibrated with ammonium (+)-camphor-10-sulfonate
(CSA) using the two-point method [39].
2.5. In Vitro Motility Assays. In vitro motility assays with
regulated thin ﬁlaments were carried out essentially as de-
scribed [8, 31, 32, 35, 40]. HMM was deposited in ﬂow cells
constructed with NC-coated coverslips. Motion of RhPh-
labeled ﬁlaments was visualized by ﬂuorescence microscopy
and a SIT camera and recorded on VHS videocassettes.
Motility assays were conducted at 30◦C unless otherwise
indicated. Control assays with unregulated F-actin were con-
ducted in actin buﬀer (AB: 25mM KCl, 25mM imidazole,
4mMMgCl 2,1m ME G T A ,1m MD T T ,a n dp H7 . 4 )[ 35]
with 2mM ATP and 0.3% methylcellulose (MC), or at pCa
5 without cTn or Tm. Solution composition for assays with
regulated thin ﬁlaments was calculated as described [8, 31,
40]. Solutions contained 2mM MgATP, 1mM Mg2+,1 0m M
EGTA, suﬃcient Ca(CH3COO)2 to achieve the desired pCa
(pCa 9–4) (pCa = −log[Ca2+], where [Ca2+]i si nm o l a r ) ,
50mMK+,1 5 m M N a +, 20mM MOPS, pH 7.00 at 30◦C,
0.5%MC, and cTn and Tm (see below). Γ/2 was adjusted
to 0.085M with TrisOH and acetic acid. To minimize
ﬂuorophore photobleaching and photo-oxidative damage to
the proteins, 3mg/mL glucose, 100μg/mL glucose oxidase,
18μg/mL catalase, and 40mM DTT were added to motility
buﬀers.
Regulated thin ﬁlaments were reconstituted in the ﬂow
cell [8, 31, 40]. Regulatory protein concentrations were
125nM in the reconstitution buﬀer and motility buﬀer.
At 125nM HcTn plus 125nM Tm, ﬁlaments were “well
regulated” as demonstrated by the absence of movement at
pCa 9 and essentially all ﬁlaments moving rapidly at pCa 5.
2.6. Temperature Dependence of Filament Sliding Speed.
Motility data were collected during continuously varying
temperature transients as described [41, 42]. Flow cells were
modiﬁed by photolithographic fabrication of a heater (thin
Au ﬁlm, 80–100nm thick) and a gold resistive thermometer
(10mm wide and 80nm thick stripes) onto opposite sides
of the glass coverslip. The heater and thermometer were
independently biased by two DC source meters (Keithley,
MODEL 2400) that also measured the voltage drop over the
thermometer stripe in a four-probe conﬁguration. Exper-
imental control and data acquisition were accomplished
with a custom LabVIEW program. Thermometers were elec-
trically insulated with GE varnish and calibrated over
the temperature range 10–70◦C. The thermoelectric heater
covered most of the ﬂow cell except for a small central win-
dow for observation of ﬁlament sliding, with the thermome-
ter stripe located ∼500μm from the window’s edge. Flow
cell heating was achieved using 0.8-0.9A current which was
turned oﬀ during cooling. The low starting temperature
(14–18◦C) and the cooling process were realized by chilled
water ﬂowing through a copper coil wrapped around the
microscope objective.
2.7. Motion Analysis. Two approaches were used to quantify
the speed of ﬁlament sliding. The ﬁrst semiautomated ap-
proach was used to determine Ca2+-dependence of sliding
speed. Digital movies were recorded directly from the video
signal or from videotape using a DC2 interface w/B&W
adapter hardware (Miglia Tech., Ltd., Chesham, UK) con-
nected to a Macintosh G4 with iMovie software. Movies were
stored in QuickTime format. Custom software for ﬁlament
tracking (motion analysis) was developed in the Linux envi-
ronment and consists of image analysis software written in
C++ with scripting andinterfacemodules writtenin Python.
The image analysis software reads as input a series of
images and outputs a list of ﬁlament paths. Initially, each
frame of the digitized sequence was converted into a binary
image using the Canny edge detection algorithm. For all
detected edges, a centroid was computed and compared
to the previous frame. Paths were constructed for objects
whose current centroid was within a user-deﬁned measure
of tolerance of its predicted value. If a centroid was outside
of these bounds, a new path was created and a current path
may be ended. Each output path thus lists every member
edge’s centroid, length, head, and tail for all constituent
frames. User-deﬁned parameters control variables such as
edge thresholding and minimum path length. Individual
ﬁlament paths were retained when the centroid could be
unambiguously tracked for ≥2s. Speed statistics were cal-
culated for each retained path. The ratio of SD/mean speed
was calculated for each path as an indicator of uniformity
of motion [32, 43], and ﬁlaments were accepted as moving
uniformly when this ratio was <0.3. For each ﬂow cell at a
given condition, the fraction of uniformly moving ﬁlaments
and their unweighted mean speed (±SD) was computed
from all retained paths; the typical number of paths analyzed
per ﬂow cell was in the hundreds.
The second approach for motion analysis was used to
determine the sliding speed of ﬁlaments during short time
intervals (e.g., during continual variation of temperature)
and to correlate sliding speed with the length of individual
ﬁlaments (e.g., duty ratio experiments). This procedure util-
ized MetaMorph (Universal Imaging) and was carried out
as described [41, 42]. Stacks of frames were created from
digitized movies, and ﬁlament paths were visualized by
superimposing all frames of one stack to form a projection
and subtracting the image of the ﬁrst frame. For each stack,
4–8 ﬁlaments were randomly selected, and the distance
traveled (d) was determined by measuring the residual con-
tour line for each ﬁlament path. Speed was determined as
d/(Δt(#frames − 1)), where Δt (Δt = 0.0333s) is deter-
mined by the 30 frames-per-second video recording. Con-
tour length of each ﬁlament was also recorded.
2.8. Cross-Bridge Duty Ratio during Unloaded Filament Slid-
ing. Cross-bridge duty ratio (f) during unloaded ﬁlament
sliding was estimated at pCa 5 using the method of Uyeda
et al.[44].Motility data wereobtained as described above for
regulated thin ﬁlaments and unregulated F-actin as a func-
tion of the density, ρ, of competent HMM on the ﬂow cell
surface, where ρ was varied by applying diﬀerent concen-
trations of HMM in the initial sequence of solutions added
to each ﬂow cell. In separate experiments, ρ was determined
from K-EDTA ATPase assays [16, 44]. Speeds of individual
ﬁlaments and their contour lengths were measured asJournal of Biomedicine and Biotechnology 5
described above. The ﬁlament length dependence of speed
was ﬁtted to an equation that describes the interaction
between myosin and actin in a stochastic manner, based on
the idea that f is equal to the probability that a myosin head
is in the strong actin-binding state of its cross-bridge cycle,
and that ﬁlaments will move at their maximum speed only if
there is at least one cross-bridge at any given time [44]:
s = η

ρ

×sm ×

1 −

1 − f
N
,( 1 )
where s is the experimentally measured speed, sm is the in-
trinsic maximum sliding speed, and η(ρ)i san u m b e rb e -
tween 0 and 1 that represents the eﬃciency by which force
generated by a single myosin head is translated into sliding
speed at a given ρ; the regression parameters are f and
η(ρ) × sm. The number of myosin motor domains (N)
available for interaction with a ﬁlament of a given length l
was calculated according to either the band model [44]:
N = 30ρl,( 2 )
where the constant 30 has units of nm and represents twice
the reach of a myosin motor domain, or the nearest neighbor
model [44, 45]:
N = l

π ×
ρ
ln2
1/2
. (3)
2.9. Statistical Analyses. Ca2+-dependence of ﬁlament sliding
speed was assessed by ﬁtting data to a modiﬁed form of
the Hill equation (4) by nonlinear least squares regression
(SigmaPlot ver. 8.0; SPSS Inc., Richmond, Calif, USA):
su =
smax
1+10 n(pCa−pCa50) +smin. (4)
Equation (4) has four regression parameters: smax is the
maximumCa2+-activatedspeedobtainedathigh[Ca2+](low
pCa); smin is the speed at low [Ca2+] (high pCa); pCa50 is
an indicator of Ca2+-sensitivity and is the pCa needed for
the value su − smin to reach 50% of smax; n is an estimate of
the slope around pCa50 and is an indicator of cooperativity.
Regression parameter estimates are given ±standard error
of the regression. Statistical diﬀerences between regression
parameterestimates(e.g.,mutantversusWT)wereevaluated
for(4)bydeterminingwhetherthediﬀerencedeviatedsignif-
icantly from zero (SigmaPlot); parameters were considered
to be signiﬁcantly diﬀerent when P<0.05.
3. Results andDiscussion
3.1. Maximum and Minimum Speeds of Filament Sliding. All
motility assays with regulated thin ﬁlaments reconstituted
with HcTn and α-GS-Tm WT, β-GS-Tm WT, or α-GS-
Tm mutants were considered to be well regulated [31, 32,
40], that is, there was little or no motion at pCa 9, and
fast uniform sliding at pCa 5 (Figure 2), indicating that
both WT and mutants support complete Ca2+-regulation
when thin ﬁlaments are saturated with regulatory proteins.
These unloaded motility data contrast with isometric force
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Figure 2: In vitro motility speeds at pCa 5 (solid bars) or pCa
9 (open bars) for regulated thin ﬁlaments (α-GS-Tm WT, α-GS-
Tm V95A, α-GS-Tm D175N, α-GS-Tm E180G, or β-GS-Tm WT
and HcTn), or at pCa 5 (solid bars) or in actin buﬀer (AB)-based
motility buﬀer (pCa ∼9; see Section 2.5) for unregulated F-actin.
Values are the weighted mean + S.D. for 4–10 ﬂow cells (weighted
by the number of ﬁlament paths tracked in each ﬂow cell).
measurements in thin ﬁlament-reconstituted cardiac prepa-
rationswhichexhibitedactiveforcegenerationintheabsence
of Ca2+ when V95A, D175N, or E180G replaced WT α-Tm
[25] although this diﬀerence may at least partially reﬂect
altered aﬃnity of mutant Tm for F-actin and/or Tn [22]a n d
experimental conditions where thin ﬁlaments may not have
beenfullysaturatedwithregulatoryproteins;itremainstobe
seen which condition more closely reﬂects diastole in FHC
patients with these mutations. Unregulated F-actin exhibited
similar speeds at both high and low [Ca2+]( Figure 2)a s
reported previously [32, 43]. At pCa 5, smax values for regu-
lated thin ﬁlaments were 53–72% faster than for unregulated
F-actin Figure 2; this result with HcTn and α-Tm agrees with
our previous report [31] and compares with the enhance-
ment of sliding speed by regulatory proteins from rabbit
skeletal muscle [32, 46]. There was no signiﬁcant diﬀerence
between the speed at pCa 5 for thin ﬁlaments reconstituted
with α-GS-Tm WT compared with any of the three mutants
orβ-GS-TmWT(Figure 2).Tmalone(i.e.,nonmutantTmin
the absence of troponin) does not enhance smax [7, 16, 17],
and, thus, this eﬀect may be more intimately linked to
troponin than Tm [7, 47], as further implicated by FHC
mutantdata(Figure 2)[8].Insupportofthisidea,mutations
D175N and E180G in human α-Tm were previously reported6 Journal of Biomedicine and Biotechnology
Table 1: Motility speed-pCa regression parameter estimates for
regulated thin ﬁlaments containing HcTn and WT or mutant
tropomyosin.
α-GS-Tm α-GS-Tm α-GS-Tm α-GS-Tm
WT V95A D175N E180G
pCa50 6.52 ±0.07 6.63 ±0.03∗ 6.72 ±0.12 7.16 ±0.03∗
N 2.3 ±0.72 .5 ±0.41 .4 ± 0.5∗ 1.7 ±0.2∗
Speed-pCa data from regulated motility assays (Figure 3)w e r eﬁ tt o( 4)
by nonlinear least squares regression (Methods). Values are regression
parameter estimates ±SE. Parameter estimates of pCa50 and n that are
signiﬁcantly diﬀerent from those for α-GS-Tm WT are indicated by ∗(P<
0.05).
to increase smax relative to WT, but only when coupled with
rabbit sTn [20, 26] and not with human cTn (Figure 2)[ 26].
The data in Figure 2 are generally compatible with
reports in which disparate experimental systems were used,
with the exception of thin ﬁlament-reconstituted cardiac
preparations at low Ca2+, that these FHC-related mutations
in α-Tm have generally small eﬀects on function at very
low or at saturating Ca2+ levels [15, 22, 25–27, 48, 49].
Decreased maximum ATPase activity and smax were found
with V95A [15, 22] although these changes were small
(<10%) and are not incompatible with our data (Figure 2).
Increased maximum isometric force was previously reported
in preparations from α-Tm E180G Tg mice [50] and thin
ﬁlament-reconstituted cardiac preparations at saturating
Ca2+ [25] although FHC-related changes in unloaded smax in
motility assays or Vmax in ﬁbers arenot necessarily associated
with corresponding changes in maximum isometric force [8,
11]. Thus, in conditions where thin ﬁlaments were saturated
with Tn and Tm, the three mutations did not signiﬁcantly
aﬀect the regulatory proteins’ ability to inhibit actomyosin
cycling at low [Ca2+] and also had little or no eﬀect on
maximum unloaded ﬁlament sliding speed.
3.2. Ca2+-Dependence of Filament Sliding. Sliding speed
increasedmonotonicallyas[Ca2+]increased(pCadecreased)
for ﬁlaments reconstituted with HcTn and α-GS-Tm WT
(Figure 3(a)) .T h ed a t aw e r ew e l lﬁ tb yt h eH i l lr e l a t i o n ,( 4)
(R2 = 0.928;Figure 3(a))andregressionparameterestimates
for pCa50 and n are given in Table 1.C a 2+-dependence of
sliding speed for regulated thin ﬁlaments containing
mutant Tm was shifted leftward (increased Ca2+-sensitivity)
relative to α-GS-Tm WT (Figures 3(b)–3(d)). Regression
estimates of pCa50 (4) increased by 0.11–0.64 pCa units
relative to α-GS-Tm WT and were signiﬁcant (P<0.05)
for the V95A and E180G mutations, although not for the
D175N mutation (Table 1). The cooperativity parameter
n (4) was signiﬁcantly reduced for both the D175N and
E180G mutations compared with WT (Table 1); this result
translated into an increase in Ca2+-responsiveness for the
D175N mutant, too, even though pCa50 was not signiﬁcantly
aﬀected (Figure 3; Table 1).
Our results with regulated thin ﬁlaments containing hu-
man α-Tm and cTn (Figure 3; Table 1) are in general agree-
ment with previous studies when direct comparisons can be
made (see Section 1), but there are also speciﬁc diﬀerences
in reported eﬀects of these Tm mutations on contractile
performance. Rat cardiac myocytes transfected with human
α-Tm D175N exhibited no eﬀect on the isometric force-pCa
relation or maximum force [48] although Tg rats expressing
human D175N exhibited a reduction in Ca2+-sensitivity of
force compared with WT [51]. Thin ﬁlament-reconstituted
cardiac preparations exhibited increased Ca2+-sensitivity of
isometric force with V95A and E180G [25], as observed
in motility assays (Figure 3; Table 1), and cooperativity was
reduced for all three mutants [25]. Where diﬀerences were
observed, they may depend on whether the assays test
isometric or isotonic function which have diﬀerent rate-lim-
iting steps although another source of variability may derive
from combining protein isoforms from diﬀerent species.
Diﬀerences could also stem from the use of homo-dimers of
Tm (both with respect to isoforms and mutations) in most
in vitro experiments, while varying proportions of homo-
and heterodimers are expected in many experiments with Tg
animal tissues or transfection of living cells. Where this has
been examined however, the functional eﬀects were linearly
related to the amount of mutant present [49].
The E180G mutation increased pCa50 of motility by 0.64
pCa units (Figure 3(d); Table 1), which is a much greater
extent than most other mutants, and similar to that observed
for the same mutant’s eﬀect on Ca2+-sensitivity of isometric
force in thin ﬁlament-reconstituted cardiac preparations
[25].Insomeotherreports,theE180Gmutantalsoincreased
Ca2+-sensitivity of various functional assays [26, 48, 50]
but by lesser extents (∼0.1–0.14pCa units). An exception
was ventricular strips from Tg rats expressing human α-
Tm E180G mutation (∼5% of Tm mRNA) that exhibited
no diﬀerence in Ca2+-sensitivity of force relative to WT and
also exhibited no cardiac hypertrophy [51]. Ca2+-sensitivity
of force increased more (∼0.3pCa units) in cardiac myocytes
from Tg mouse hearts expressing ∼65% α-Tm E180G, with
a linear correlation between ΔpCa50 and fraction of α-Tm
E180G that extrapolated to a large, ∼0.4pCa unit shift at
100%α-Tm E180G [49].
These diﬀerences in Ca2+-sensitivity due to FHC-related
mutationsareinthesamedirectionasobservedwiththreeC-
terminal FHC-related mutations in cTnI although the cTnI
mutants also exhibited substantial increases in smax [8]. α-
Tm and cTnI mutants could aﬀect smax diﬀerently because of
diﬀerences in the molecular mechanisms by which cTnI and
α-Tm mutants alter thin ﬁlament activation, or because of
diﬀerent sources for the regulatory proteins.
3.3. CD Spectroscopy. Ca2+-sensitizing eﬀects of the FHC
mutations (Figure 3; Table 1) may be related to changes
in Tm structure and are thus downstream in the signaling
pathway from Ca2+ binding to TnC. Figure 4 shows CD
spectra obtained from the ﬁve Tm samples. Each spectrum
in Figure 4 is the average of 2-3 independent determinations
from diﬀerent batches of protein and each determination is
the average of 3 scans. Spectra were quantiﬁed from [θ]222
and also by more extensive analysis (see Section 2)w i t h
CDPro software (Table 2). Both methods of analysis yielded
similar, high estimates of α-helix content for both WT α-
and β-Tm (78–85%) as expected for a protein that is largelyJournal of Biomedicine and Biotechnology 7
S
S
p
e
e
d
(
μ
m
e
c
−
1
)
0
2
4
6
8
10
α-WT
4 5 6 7 8 9
pCa
(a)
V95A
0
0.2
0.4
0.6
0.8
1.0
1.2
S
p
e
e
d
(
n
o
r
m
a
l
i
z
e
d
)
pCa
4 5 6 7 8 9
(b)
D175N
4 5 6 7 8 9
pCa
S
p
e
e
d
(
n
o
r
m
a
l
i
z
e
d
)
0
0.2
0.4
0.6
0.8
1
1.2
(c)
S
p
e
e
d
(
n
o
r
m
a
l
i
z
e
d
)
pCa
4 5 6 7 8 9
0
0.2
0.4
0.6
0.8
1.0
1.2
E180G
(d)
Figure 3: Ca2+-dependence of in vitro motility speed for regulated thin ﬁlaments reconstituted with HcTn and either, (a) α-GS-Tm WT (•),
(b) α-GS-Tm V95A (), (c) α-GS-Tm D175N (), or (d) α-GS-Tm E180G (). In (b–d), data and regressions for each Tm were normalized
to smax + smin from regression (4) for the same Tm. Each point represents the mean for one ﬂow cell; error bars in (b–d) are comparable to
those in (a). Solid lines are nonlinear least squares regression ﬁts of the mutant Tm data to (4), and parameter estimates are given in Table 1.
For comparison, the regression line for α-GS-Tm WT (a) was normalized as described above and plotted in panels (b–d) as a dotted line for
reference.
α-helical coiled coil. CDPro and [θ]222 analyses indicated
that α-helix content was lower in the three mutant proteins
(61–73%;Table 2).Lowerα-helixcontentofthemutantTm’s
was correlated with higher fractions of unordered structure
in CDPro analysis (Table 2). The V95A mutant had the
lowest α-helix content, and reduced α-helix content of the
E180G mutant is consistent with prediction from the COILS
algorithm [52] of local destabilization around the mutation.
3.4. α-Tropomyosin E180G Mutation Alters Temperature Sen-
sitivityofFilamentSlidingatpCa5. Inadditiontoreducedα-
helixcontentat25◦C(Figure 4),theE180Gmutantexhibited
decreased stability to thermal unfolding in the presence or
absence of actin [21, 24]. To test whether these structural
changes are associated with functional eﬀects in addition
to the marked increase in Ca2+-sensitivity (Figure 3(d)), we
used a novel method for continuously varying temperature
in motility assays [41, 42].
Speed of thin ﬁlaments reconstituted with α-Tm WT at
pCa 5 increased with increasing temperature up to at least
50◦C( Figure 5, open circles; note that these control data are
a subset of the WT-regulated thin ﬁlament data replotted
from Brunet et al. [42]). Above ∼54◦C, thin ﬁlaments
reconstituted with WT Tm/Tn exhibit an anomalous decline
in sliding speed [42] that is likely due to dissociation of
regulatory proteins from actin [24] and/or denaturation of8 Journal of Biomedicine and Biotechnology
Table 2: Estimates of structural content of WT and mutant tropomyosins.
α-helix (%) β-sheet (%) β-turn (%) Unordered (%)
[θ]222 CDPro CDPro CDPro CDPro
α-GS-Tm WT 84.5 ±4.67 9 .1 ±10.84 .3 ±3.47 .0 ±6.71 0 .4 ±5.8
α-GS-Tm V95A 60.6 ±10.46 2 .7 ± 6.48 .2 ±3.21 2 .2 ±3.51 7 .0 ±5.1
α-GS-Tm D175N 72.1 ±0.77 2 .9 ± 7.05 .6 ±3.71 1 .3 ±5.51 3 .3 ±6.0
α-GS-Tm E180G 69.7 ±3.36 7 .9 ± 5.65 .9 ±2.79 .5 ±4.71 7 .3 ±3.7
β-GS-Tm WT 83.6 ±6.47 7 .8 ±13.15 .2 ±4.47 .8 ±6.51 0 .1 ±8.8
Estimates of structural content for each of the ﬁve recombinant Tm’s wereobtained from analyses of the individualCD spectra that were averaged for Figure 4.
α-helical content was estimated from [θ]222 (Methods). Content of α-helix, β-sheet, and unordered structure was obtained using CDPro software (Methods).
Values are mean ± S.D. (N = 2-3 spectra); note that, for CDPro estimates, S.D. is the mean of S.D. values from CDPro.
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Figure 4: Circular dichroism spectra of WT and mutant recombi-
nant tropomyosins in solution. Each spectrum is the average of 2-
3 independent determinations. Estimates of structural content are
given in Table 2. Note that curves for α-GS-Tm WT and β-GS-Tm
WT overlap over most of the wavelength range.
Tm or Tn at elevated temperatures. Filament speed declines
to that of unregulated F-actin [42] because actin and HMM
denature at higher temperatures than Tm/Tn during these
brief excursions to high temperatures.
When the assay was repeated with thin ﬁlaments recon-
stituted with α-Tm E180G (Figure 5, solid squares), the
temperature dependence of speed deviated from WT at
temperatures slightly above body temperature. At these
higher temperatures, sliding speed was slower with mutant
Tm than with WT. Above ∼44◦C, there is a deﬂection in
the speed-temperature relation for thin ﬁlaments reconsti-
tuted with α-Tm E180G (Figure 5). This deﬂection is likely
indicative of structural destabilization, denaturation, and/or
dissociation of mutant regulatory proteins at a substantially
lower temperature (∼10◦C lower) than for WT and is also
indicative of a strong functional correlate of diﬀerential
scanning calorimetry (DSC) measurements in solution [24].
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Figure 5: Temperature dependence of sliding speed at pCa 5 for
regulated thin ﬁlaments reconstituted with HcTn and either α-GS-
Tm E180G ()o rα-GS-Tm WT ( ) [note that the control WT
data are a subset of regulated thin ﬁlament data replotted from
[42]]. Data were obtained during the heating phase of two cycles of
heating and cooling in ﬂow cells conﬁgured with a microfabricated
thermo-electric heater for continuous variation of temperature (see
Section 2). Points represent mean of the sliding speed for 3–8
ﬁlaments during one second. Note the deviation of mutant Tm data
from WT as temperature increases.
The substantial increase in Ca2+-sensitivity associated
with the E180G mutation (Figure 3; Table 1)i st h u sc o r -
related with reduced aﬃnity for actin in vitro in the ab-
sence of Tn [20–22], destabilization of Tn binding to F-
actin-Tm [22], reduced α-helix content (Figure 4; Table 2),
and reduced thermal stability of structure [21, 24]a n d
function (Figure 5). Structural destabilization of α-Tm by
FHC mutations could reduce ﬂexural rigidity, as suggested
by Heller et al. [23] when considering other FHC-related
mutations in α-Tm; modeling suggests that changes in pro-
tein compliance within sarcomeres could markedly aﬀectJournal of Biomedicine and Biotechnology 9
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Figure 6: Cross-bridge duty ratio (f ) during unloaded sliding of
regulated thin ﬁlaments reconstituted with HcTn and either α-GS-
Tm WT, α-GS-Tm D175N, or α-GS-Tm E180G is lower than for
unregulated F-actin. Duty ratio was estimated using the method
of Uyeda et al. [61]b yv a r y i n gH M Md e n s i t y( ρ)a sd e s c r i b e d
in Materials and Methods (see Section 2.8). Estimates of f were
obtained by applying the band model and were normalized to
the value obtained for WT at the same ρ. Bars indicate average
normalized f for all ρ (n = 5 − 8); error bars indicate S.D.
Duty ratios for all three types of regulated thin ﬁlaments were
signiﬁcantly lower than for unregulated F-actin (∗∗P<0.01) but
were not statistically diﬀerent from each other (P>0.05).
muscle function [53–56]. The details of this mechanism
are therefore distinct from the likely molecular basis for
Ca2+-sensitization by FHC-related mutations in the COOH-
terminus of cTnI [8, 57]. Flexibility of Tm is clearly im-
portant for its structure and function [58]a n dc h a n g e s
related to FHC mutations could lead to a decrease in the
already low-energy barrier for movement of Tm on actin
[59]; detailed structural studies are needed to clarify the in-
ﬂuence of FHC mutations on Tm structure and ﬂexibility. In
addition, coupling between adjacent regulatory units could
be aﬀected, as suggested by reduced cooperativity with the
E180G mutation (Figure 3(d); Table 1)[ 25]. Signiﬁcantly,
the reduced thermal stability of thin ﬁlaments containing the
E180G mutant α-Tm illustrated in Figure 5 suggests that pa-
tients with the FHC mutation could be more susceptible to
diastolicdysfunction,andpossiblysuddencardiacdeath,due
to thin ﬁlament dysregulation during heavy exercise [24].
3.5. Dependence of Regulated Thin Filament Sliding at pCa
5 on Cross-Bridge Density and Number. Mutations in α-Tm
could modulate the dependence of thin ﬁlament activation
on cross-bridges and cross-bridge number [60]. To examine
this possibility for the D175N and E180G mutations—the
two mutations associated with the largest eﬀects on Ca2+-
responsiveness (Figure 3)—we measured sliding speed of
regulated thin ﬁlaments at pCa 5 by varying the density of
functional HMM (ρ)o nt h eﬂ o wc e l ls u r f a c e[ 44]. For each
condition (Tm and ρ), speed (s) and the length (l) of indi-
vidual ﬁlaments were used to determine η(ρ) × sm and acto-
myosin duty ratio (f;( 1)) as described (see Section 2)[ 44].
Figure 6 shows that f was lower for WT-reconstituted thin
ﬁlamentsthanforunregulatedF-actin,andthat f wassimilar
for reconstituted thin ﬁlaments containing WT Tm or either
of the two Tm mutants examined. Estimates of f in Figure 6
were obtained using the band model (2)a n dw e r ea v e r a g e d
forallρ.Theseresultsshowthatthestructuralandfunctional
changes associated with mutants D175N and E180G of α-
Tm do not lead to substantial changes in actomyosin duty
ratio relative to WT-regulated thin ﬁlaments, consistent with
regulated thin ﬁlament sliding speed being similar at sat-
urating HMM density (Figure 2), and the distribution of
cross-bridgestatesfromsinusoidalanalysisofisometricforce
in thin ﬁlament-reconstituted cardiac preparations [25].
For regulated thin ﬁlaments at pCa 5, sm is a hyperbolic
function of ρ (Figure 7). The ρ-dependence of η(ρ) × sm
was indistinguishable for α-Tm E180G compared with α-
Tm WT (Figure 7). Thin ﬁlaments reconstituted with α-Tm
D175N, on the other hand, exhibited motility and achieved
maximumslidingspeedatlowerρ’sthaneitherE180GorWT
(Figure 7). These results indicate that the D175N and E180G
mutations increase Ca2+-responsiveness of ﬁlament sliding
(Figure 3;Table 1)byverydiﬀerentmechanismseventhough
the two mutations reside in close proximity and have similar
eﬀects on overall α-helical content as detected by CD spec-
troscopy (Figure 4). The data in Figures 3 and 7 suggest that
eﬀects of the D175N would be most evident at low levels of
thinﬁlamentactivationwherethenumberofcross-bridgesis
small, and additional cross-bridges have the greatest impact.
3.6. Conclusions. Functional and structural diﬀerences in
three FHC-related mutations in α-Tm (V95A, D175N, and
E180G) were found using both conventional and modiﬁed
in vitro motility assays and CD spectroscopy. Mutant Tm’s
exhibited lower α-helical content and more unordered
structure than α-GS-Tm WT; these structural changes could
result in alterations in ﬂexural rigidity that, in turn, could be
responsible for increased Ca2+-responsiveness of regulated
ﬁlament sliding that was observed with the mutants. α-GS-
Tm E180G exhibited the greatest enhancement of Ca2+-
responsiveness of the mutants studied due to both a large
increaseinpCa50 andareductioninn,anddysregulationat∼
10◦C lower temperature than WT. α-GS-Tm V95A exhibited
a smaller but signiﬁcant increase in pCa50. α-GS-Tm D175N
exhibited lower n and a marked reduction in the minimum
density of HMM necessary for initiating ﬁlament sliding and
for achieving maximum sliding speed at saturating Ca2+.
Thesestructuralandfunctionalchangesprovideinsightsinto
molecular mechanisms of pathological cardiac hypertrophy.
Increased Ca2+-responsiveness of cardiac myoﬁbrillar
function appears to be a common feature of FHC-related10 Journal of Biomedicine and Biotechnology
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Figure 7: HMM density (ρ) dependence of maximum unloaded
ﬁlament sliding speed (sm) of regulated thin ﬁlaments reconstituted
with HcTn and either α-GS-Tm WT ( ), α-GS-Tm D175N (),
or α-GS-Tm E180G (). sm was obtained at each ρ according to
the method of Uyeda et al. [61] as described in Section 2.8;e a c h
point is from one ﬂow cell. Note that sm(ρ) for thin ﬁlaments
containing α-GS-Tm D175N is shifted leftward of that for thin
ﬁlaments containing either α-GS-Tm WT or α-GS-Tm E180G.
mutations in α-Tm, cTnI, and cTnT (Figure 3)[ 8, 13, 15, 23,
25–27, 29, 48, 50, 62]. The extent of enhancement of Ca2+-
sensitivity is generally associated with clinical prognosis in
FHC patients [57, 63] although it is not generally known
the extent to which function in vivo with variable ratios of
WT and mutant homo-dimers, and also presumptive hetero-
dimers, might diﬀer from that found using in vitro assays
with pure homo-dimers such as those described here. Func-
tional consequences of increased Ca2+-sensitivity in the liv-
ing heart, in the absence of adaptive responses, are expected
to be slowed relaxation and increased duration of systole
because the intracellular Ca2+ transient does not normally
achievesuﬃcientlyhighCa2+ concentrationstosaturateTnC
[56]. Observations on intact hearts from Tg mice with α-Tm
mutation E180G are consistent with these expectations [28,
29, 49]. Thus, there are clear possibilities for direct links be-
tween thin ﬁlament mutations and hypertrophic signaling
through altered mechanical and energetic load, and/or
altered Ca2+-cycling in myocytes [56].
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